Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies

Area of Science:

• Pharmacology and Pharmaceutical Sciences
• Pediatric Medicine
• Nanotechnology in Drug Delivery

Background:

• Pediatric drug development historically relies on "carrot-and-stick" tactics to address population-specific needs.
• Off-label prescription of adult medications in children persists, potentially compromising age-appropriate treatment evaluation.
• Regulatory bodies recommend nanotechnology-based delivery systems to overcome pediatric formulation challenges.

Purpose of the Study:

• To review the current landscape of pediatric drug development.
• To outline the historical regulatory framework for pediatric medicines.
• To summarize formulation challenges and explore innovative approaches like nanomedicines and ATMPs for pediatric use.

Main Methods:

• Literature review and synthesis of regulatory guidelines.
• Analysis of challenges in pediatric drug formulation.
• Evaluation of the advantages and disadvantages of nanomedicines and advanced therapy medicinal products (ATMPs) in pediatrics.

Main Results:

• Nanotechnology-based delivery systems (inorganic, polymeric, lipid-based nanoparticles) are recommended for pediatric drug formulation.
• Advanced therapy medicinal products (ATMPs) show promise for pediatric applications.
• A multidisciplinary workforce is crucial for standardizing guidelines and accelerating lab-to-clinical translation.

Conclusions:

• Innovative approaches like nanomedicines and ATMPs are vital for advancing pediatric drug development.
• Addressing formulation challenges and regulatory hurdles is essential for safe and effective pediatric medicines.
• Enhanced collaboration among stakeholders is necessary to optimize the translation of novel therapies to pediatric patients.